Pyxis Oncology is a biotechnology firm that develops antibody therapeutics intended to promote the body's immune response to cancer.
Pyxis Oncology has raised $110.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2026.
Pyxis Oncology's investors include RA Capital Management, Perceptive Advisors, Janus Henderson Investors, Blue Owl, RTW Investments.
Pyxis Oncology is headquartered in Boston, United States.
Pyxis Oncology is a biotechnology firm that develops antibody therapeutics intended to promote the body's immune response to cancer.
Pyxis Oncology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pyxis Oncology — Funding & Investors." VCBacked, September 29, 2026, https://www.vcbacked.co/company/pyxis-oncology. Accessed October 12, 2026.
VCBacked. (2026). Pyxis Oncology — Funding & Investors. Retrieved October 12, 2026, from https://www.vcbacked.co/company/pyxis-oncology
{{cite web |title=Pyxis Oncology — Funding & Investors |url=https://www.vcbacked.co/company/pyxis-oncology |website=VCBacked |access-date=October 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated